• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全国范围内多发性与首次皮肤鳞状细胞癌的发病率及皮肤鳞状细胞癌未来发病率的估计。

Incidence of Multiple vs First Cutaneous Squamous Cell Carcinoma on a Nationwide Scale and Estimation of Future Incidences of Cutaneous Squamous Cell Carcinoma.

机构信息

Department of Dermatology, Erasmus Medical Center, Rotterdam, the Netherlands.

Department of Research & Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands.

出版信息

JAMA Dermatol. 2020 Dec 1;156(12):1300-1306. doi: 10.1001/jamadermatol.2020.3677.

DOI:10.1001/jamadermatol.2020.3677
PMID:33112377
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7593880/
Abstract

IMPORTANCE

Until now, most studies on cutaneous squamous cell carcinoma (cSCC) incidence rates concerned only the first cSCC per patient. Given the increase in incidence rates and the frequent occurrence of subsequent cSCCs per patient, population-based data on the incidence rates of both first and multiple cSCCs are needed.

OBJECTIVES

To calculate annual age-standardized incidence rates for histopathologically confirmed first and multiple cSCCs per patient and to estimate future cSCC incidence rates up to 2027.

DESIGN, SETTING, AND PARTICIPANTS: A nationwide population-based epidemiologic cohort study used cancer registry data on 145 618 patients with a first histopathologically confirmed cSCC diagnosed between January 1, 1989, and December 31, 2017, from the Netherlands Cancer Registry and all patients with multiple cSCCs diagnosed in 2017.

MAIN OUTCOMES AND MEASURES

Age-standardized incidence rates for cSCC-standardized to the European Standard Population 2013 and United States Standard Population 2000-were calculated per sex, age group, body site, and disease stage. A regression model with positive slope was fitted to estimate cSCC incidence rates up to 2027.

RESULTS

A total of 145 618 patients in the Dutch population (84 572 male patients [58.1%]; mean [SD] age, 74.5 [11.5] years) received a diagnosis of a first cSCC between 1989 and 2017. Based on incident data, European Standardized Rates (ESRs) increased substantially, with the highest increase found among female patients from 2002 to 2017, at 8.2% (95% CI, 7.6%-8.8%) per year. The ESRs for first cSCC per patient in 2017 were 107.6 per 100 000 person-years (PY) for male patients, an increase from 40.0 per 100 000 PY in 1989, and 68.7 per 100 000 PY for female patients, an increase from 13.9 per 100 000 PY in 1989, which corresponds with a US Standardized Rate of 71.4 per 100 000 PY in 2017 for men and 46.4 per 100 000 PY in 2017 for women. Considering multiple cSCCs per patient, ESRs increased by 58.4% for men (from 107.6 per 100 000 PY to 170.4 per 100 000 PY) and 34.8% for women (from 68.7 per 100 000 PY to 92.6 per 100 000 PY). Estimation of ESRs for the next decade show a further increase of 23.0% for male patients (ESR up to 132.4 per 100 000 PY [95% prediction interval, 125.8-139.0 per 100 000 PY]) and 29.4% for female patients (ESR up to 88.9 per 100 000 PY [95% prediction interval, 84.3-93.5 per 100 000 PY]).

CONCLUSIONS AND RELEVANCE

This nationwide epidemiologic cohort study suggests that incidence rates of cSCC keep increasing, especially among female patients, and that the occurrence of multiple cSCCs per patient significantly adds to the current and future burden on dermatologic health care. Revision of skin cancer policies are needed to halt this increasing trend.

摘要

重要性

到目前为止,大多数关于皮肤鳞状细胞癌(cSCC)发病率的研究仅涉及每位患者的首次 cSCC。鉴于发病率的增加以及每位患者随后发生的 cSCC 的频繁发生,需要基于人群的数据来了解首次和多次 cSCC 的发病率。

目的

计算每位患者首次和多次病理证实的 cSCC 的年龄标准化发病率,并估计到 2027 年的未来 cSCC 发病率。

设计、地点和参与者:一项全国性基于人群的流行病学队列研究使用了荷兰癌症登记处 1989 年 1 月 1 日至 2017 年 12 月 31 日期间诊断的 145618 例首次病理证实的 cSCC 患者以及 2017 年诊断的所有多次 cSCC 患者的癌症登记数据。

主要结果和测量

根据欧洲标准人口 2013 年和美国标准人口 2000 年进行标准化的 cSCC 年龄标准化发病率,按性别、年龄组、身体部位和疾病阶段进行计算。使用正斜率回归模型来估计到 2027 年的 cSCC 发病率。

结果

荷兰人群中共有 145618 例患者(84572 例男性患者[58.1%];平均[标准差]年龄为 74.5[11.5]岁)在 1989 年至 2017 年期间诊断出首次 cSCC。根据发病数据,欧洲标准化发病率(ESR)大幅增加,其中女性患者从 2002 年到 2017 年的增长率最高,为每年 8.2%(95%置信区间,7.6%-8.8%)。2017 年每位患者首次 cSCC 的 ESR 为男性患者 107.6/100000 人年,比 1989 年的 40.0/100000 人年增加,女性患者为 68.7/100000 人年,比 1989 年的 13.9/100000 人年增加,这与 2017 年男性患者的美国标准化发病率 71.4/100000 人年和女性患者的 46.4/100000 人年相对应。考虑到每位患者的多次 cSCC,男性患者的 ESR 增加了 58.4%(从 107.6/100000 人年增加到 170.4/100000 人年),女性患者的 ESR 增加了 34.8%(从 68.7/100000 人年增加到 92.6/100000 人年)。对未来十年 ESR 的估计显示,男性患者的发病率进一步增加 23.0%(ESR 高达 132.4/100000 人年[95%预测区间,125.8-139.0/100000 人年]),女性患者的发病率增加 29.4%(ESR 高达 88.9/100000 人年[95%预测区间,84.3-93.5/100000 人年])。

结论和相关性

这项全国性的基于人群的流行病学队列研究表明,cSCC 的发病率持续上升,尤其是在女性患者中,每位患者多次发生 cSCC 的情况显著增加了当前和未来皮肤保健的负担。需要修订皮肤癌政策以阻止这一上升趋势。

相似文献

1
Incidence of Multiple vs First Cutaneous Squamous Cell Carcinoma on a Nationwide Scale and Estimation of Future Incidences of Cutaneous Squamous Cell Carcinoma.全国范围内多发性与首次皮肤鳞状细胞癌的发病率及皮肤鳞状细胞癌未来发病率的估计。
JAMA Dermatol. 2020 Dec 1;156(12):1300-1306. doi: 10.1001/jamadermatol.2020.3677.
2
Assessment of Cutaneous Squamous Cell Carcinoma (cSCC) In situ Incidence and the Risk of Developing Invasive cSCC in Patients With Prior cSCC In situ vs the General Population in the Netherlands, 1989-2017.评估荷兰 1989-2017 年期间,既往原位皮肤鳞状细胞癌(cSCC)患者与普通人群相比,原位 cSCC 的发生率及发展为侵袭性 cSCC 的风险。
JAMA Dermatol. 2020 Sep 1;156(9):973-981. doi: 10.1001/jamadermatol.2020.1988.
3
Nationwide Incidence of Metastatic Cutaneous Squamous Cell Carcinoma in England.英格兰转移性皮肤鳞状细胞癌的全国发病率。
JAMA Dermatol. 2019 Mar 1;155(3):298-306. doi: 10.1001/jamadermatol.2018.4219.
4
Association of Age, Sex, Race, and Geographic Region With Variation of the Ratio of Basal Cell to Cutaneous Squamous Cell Carcinomas in the United States.年龄、性别、种族和地理位置与美国基底细胞癌与皮肤鳞状细胞癌比率变化的关联。
JAMA Dermatol. 2020 Nov 1;156(11):1192-1198. doi: 10.1001/jamadermatol.2020.2571.
5
Epidemiology of basal and cutaneous squamous cell carcinoma in the U.K. 2013-15: a cohort study.英国 2013-2015 年基底细胞和皮肤鳞状细胞癌的流行病学:一项队列研究。
Br J Dermatol. 2019 Sep;181(3):474-482. doi: 10.1111/bjd.17873. Epub 2019 May 6.
6
Cumulative incidence and timing of subsequent cutaneous squamous cell carcinomas stratified for patients with organ transplantation and hematologic malignancies: A nationwide cohort study.根据器官移植和血液系统恶性肿瘤患者分层的后续皮肤鳞状细胞癌的累积发病率和发病时间:一项全国性队列研究。
J Am Acad Dermatol. 2024 Mar;90(3):530-536. doi: 10.1016/j.jaad.2023.10.036. Epub 2023 Oct 21.
7
Outcomes of Patients With Multiple Cutaneous Squamous Cell Carcinomas: A 10-Year Single-Institution Cohort Study.多发性皮肤鳞状细胞癌患者的预后:一项 10 年单机构队列研究。
JAMA Dermatol. 2015 Nov;151(11):1220-5. doi: 10.1001/jamadermatol.2015.1702.
8
Risk factors and timing of subsequent cutaneous squamous cell carcinoma in patients with cutaneous squamous cell carcinoma: A retrospective cohort study.患有皮肤鳞状细胞癌的患者中后续皮肤鳞状细胞癌的风险因素和时间:一项回顾性队列研究。
J Am Acad Dermatol. 2021 Mar;84(3):719-724. doi: 10.1016/j.jaad.2020.08.083. Epub 2020 Aug 27.
9
Invasive and in situ squamous cell carcinoma of the skin: a nationwide study in Iceland.皮肤的浸润性和原位鳞状细胞癌:冰岛的一项全国性研究。
Br J Dermatol. 2021 Sep;185(3):537-547. doi: 10.1111/bjd.19879. Epub 2021 May 9.
10
Incidence, mortality and trends of cutaneous squamous cell carcinoma in Germany, the Netherlands, and Scotland.德国、荷兰和苏格兰皮肤鳞状细胞癌的发病率、死亡率和趋势。
Eur J Cancer. 2023 Apr;183:60-68. doi: 10.1016/j.ejca.2023.01.017. Epub 2023 Jan 28.

引用本文的文献

1
Frequency and timing of multiple skin cancer development in five cohorts.五个队列中多发性皮肤癌发生的频率和时间
J Am Acad Dermatol. 2025 Jun;92(6):1295-1302. doi: 10.1016/j.jaad.2024.12.047. Epub 2025 Feb 8.
2
Mutational Landscapes of Normal Skin and Their Potential Implications in the Development of Skin Cancer: A Comprehensive Narrative Review.正常皮肤的突变图谱及其在皮肤癌发生中的潜在影响:一项全面的叙述性综述
J Clin Med. 2024 Aug 15;13(16):4815. doi: 10.3390/jcm13164815.
3
Recent Changes in the Incidence and Characteristics of Cutaneous Squamous Cell Carcinomas in Finland from 2006 to 2020: A Retrospective Cohort Study.2006 至 2020 年芬兰皮肤鳞状细胞癌发病率和特征的近期变化:一项回顾性队列研究。
Acta Derm Venereol. 2024 May 30;104:adv39891. doi: 10.2340/actadv.v104.39891.
4
Toward personalized skin cancer care: multiple skin cancer development in five cohorts.迈向个性化皮肤癌护理:五个队列中的多发性皮肤癌发展情况
medRxiv. 2024 May 7:2024.05.06.24306947. doi: 10.1101/2024.05.06.24306947.
5
T Cell Immunity in Human Papillomavirus-Related Cutaneous Squamous Cell Carcinoma-A Systematic Review.人乳头瘤病毒相关皮肤鳞状细胞癌中的T细胞免疫——一项系统综述
Diagnostics (Basel). 2024 Feb 21;14(5):473. doi: 10.3390/diagnostics14050473.
6
Epidemiology of Keratinocyte Skin Cancer with a Focus on Cutaneous Squamous Cell Carcinoma.以皮肤鳞状细胞癌为重点的角质形成细胞皮肤癌流行病学
Cancers (Basel). 2024 Jan 31;16(3):606. doi: 10.3390/cancers16030606.
7
Targeting tumor-associated macrophages: Novel insights into immunotherapy of skin cancer.靶向肿瘤相关巨噬细胞:皮肤癌免疫治疗的新见解
J Adv Res. 2025 Jan;67:231-252. doi: 10.1016/j.jare.2024.01.013. Epub 2024 Jan 17.
8
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma.抗 PD-L1 抗体 cosibelimab 治疗转移性皮肤鳞状细胞癌的疗效和安全性。
J Immunother Cancer. 2023 Oct;11(10). doi: 10.1136/jitc-2023-007637.
9
Personalised decision making to predict absolute metastatic risk in cutaneous squamous cell carcinoma: development and validation of a clinico-pathological model.预测皮肤鳞状细胞癌绝对转移风险的个性化决策:一种临床病理模型的开发与验证
EClinicalMedicine. 2023 Aug 19;63:102150. doi: 10.1016/j.eclinm.2023.102150. eCollection 2023 Sep.
10
Small intestinal perforation secondary to metastasis from skin squamous cell carcinoma: A case report and literature review.皮肤鳞状细胞癌转移继发小肠穿孔:一例报告及文献复习
Int J Surg Case Rep. 2023 Aug;109:108599. doi: 10.1016/j.ijscr.2023.108599. Epub 2023 Aug 2.

本文引用的文献

1
Epidemiology of basal and cutaneous squamous cell carcinoma in the U.K. 2013-15: a cohort study.英国 2013-2015 年基底细胞和皮肤鳞状细胞癌的流行病学:一项队列研究。
Br J Dermatol. 2019 Sep;181(3):474-482. doi: 10.1111/bjd.17873. Epub 2019 May 6.
2
Characteristics and Trends of Cutaneous Squamous Cell Carcinoma in a Patient Cohort in Finland 2006-2015.2006-2015 年芬兰患者队列中皮肤鳞状细胞癌的特征和趋势。
Acta Derm Venereol. 2019 Apr 1;99(4):412-416. doi: 10.2340/00015555-3110.
3
Incidence, demographics and surgical outcomes of cutaneous squamous cell carcinoma diagnosed in Northland, New Zealand.在新西兰北地被诊断出的皮肤鳞状细胞癌的发病率、人口统计学特征及手术结果
N Z Med J. 2018 May 18;131(1475):61-68.
4
Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging.皮肤鳞状细胞癌:发病率、危险因素、诊断和分期。
J Am Acad Dermatol. 2018 Feb;78(2):237-247. doi: 10.1016/j.jaad.2017.08.059.
5
The incidence and multiplicity rates of keratinocyte cancers in Australia.澳大利亚的角质形成细胞癌的发病率和多发性率。
Med J Aust. 2017 Oct 16;207(8):339-343. doi: 10.5694/mja17.00284.
6
Epidemiology of basal and squamous cell carcinoma in Belgium: the need for a uniform and compulsory registration.比利时基底细胞和鳞状细胞癌的流行病学:需要统一和强制登记。
J Eur Acad Dermatol Venereol. 2016 Nov;30(11):1912-1918. doi: 10.1111/jdv.13703. Epub 2016 Jun 3.
7
Outcomes of Patients With Multiple Cutaneous Squamous Cell Carcinomas.多发性皮肤鳞状细胞癌患者的预后
JAMA Oncol. 2016 Jan;2(1):130-1. doi: 10.1001/jamaoncol.2015.3894.
8
Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012.美国 2012 年人群中非黑色素瘤皮肤癌(角质形成细胞癌)的发病率估计。
JAMA Dermatol. 2015 Oct;151(10):1081-6. doi: 10.1001/jamadermatol.2015.1187.
9
Cutaneous squamous cell carcinoma in Norway 1963-2011: increasing incidence and stable mortality.1963年至2011年挪威皮肤鳞状细胞癌:发病率上升,死亡率稳定。
Cancer Med. 2015 Mar;4(3):472-80. doi: 10.1002/cam4.404. Epub 2015 Jan 26.
10
Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis.先前患有角化细胞癌患者继发皮肤恶性肿瘤的风险:系统评价和荟萃分析。
Eur J Cancer. 2013 Jul;49(10):2365-75. doi: 10.1016/j.ejca.2013.03.010. Epub 2013 Apr 20.